Cited by 229Diabetes Management and ResearchDiabetes Management and EducationDiabetes Treatment and Management

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

Open access

Silva, Julien Da, Lepore, Giuseppe, Battelino, Tadej, Arrieta, Arcelia, Castañeda, Javier, Grossman, Benyamin, Shin, John, Cohen, Ohad·2022·Diabetes Technology & Therapeutics

DOI 10.1089/dia.2021.0203PMC PMC8817690

Open this paper in CoChat — free account

Abstract

Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Methods: Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation. Results: Users ( N = 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible ( N = 812) reduced their GMI by 0.4% ± 0.4% ( P = 0.005) and increased their TIR by 12.1% ± 10.5% ( P < 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%, P < 0.0001) and TIR >70% (34.6% vs. 74.9%, P < 0.0001) when compared with pre-AHCL initiation. Conclusion: Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1089/dia.2021.0203

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“The new parameters are born from the growing use of CGM measurements of time spent in different ranges with consensus on definitions of ranges and current goals.(1) For people with T1DM, except during pregnancy, the goals are to spend >70% of the time between the range of 70–180 mg/dL, <4% below 70 mg/dL, <1% below 54…”
BackgroundSelf-citation
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies
Ioannidis, J. P. A. (2001) · JAMA · doi:10.1001/jama.286.7.821 · Cited by 919
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study
Holman, N., Knighton, P., Kar, P., O'Keefe, J., Curley, M., Weaver, A., Barron, E., Bakhai, C., Khunti, K., Wareham, N. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30271-0 · Cited by 908
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & SKOLNIK, N. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 757
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 1×
“Users with ‡10 days of sensor glucose (SG) data after AHCL was enabled for the first time (post-AHCL) were included in the analysis, based on previous publications using a similar duration of time to estimate or determine CGM-derived metrics.(13,14) All data available were included, whether the system was in AHCL cont…”
Method
Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citation
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 3

Da Silva J, , Arrieta A, , Castaneda J, et al.: Real-world Performance of the MiniMed™ 780G System: impact of initiating automated basal and correction boluses. Diabetes Technol Ther, 2021; 23:A79–A80.
Habif S, , Singh H, , Manning M, et al.: Quality of life outcomes and glycemic control from the T:slim X2 Pump with Control-IQ Technology—Real World Observations from the CLIO Study. Diabetes Technol Ther, 2021; 23:A-66.
Da Silva J, , Velado K, , Agrawal P, et al.: Real-life use and performance of the MiniMed™ 670G System in Europe. Diabetes Technol Ther, 2020; 22:A96–A97.

Sorted by citations

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citation
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Current state of the art and future directions for implantable sensors in medical technology: Clinical needs and engineering challenges
Yogev, D., Goldberg, T., Arami, A., Tejman‐Yarden, S., Winkler, T. E., & Maoz, B. M. (2023) · APL Bioengineering · doi:10.1063/5.0152290 · Cited by 147
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system
Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Silva, J. D., Shin, J., & Cohen, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14807 · Cited by 108
Self-citation
Simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system: a randomized controlled trial comparing glucose control
Petrovski, G., Campbell, J., Pasha, M., Day, E., Hussain, K., Khalifa, A., & van den Heuvel, T. (2023) · Diabetes Care · doi:10.2337/dc22-1692 · Cited by 108
Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence
Choudhary, P., Arrieta, A., van den Heuvel, T. R. A., Castañeda, J., Smaniotto, V., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0433 · Cited by 83
Self-citation
Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed-loop system: a two-center, randomized, controlled study
Matejko, B., Juza, A., Kieć-Wilk, B., Cyranka, K., Krzyżowska, S., Chen, X., Cohen, O., Da Silva, J., Malecki, M. T., & Klupa, T. (2022) · Diabetes Care · doi:10.2337/dc22-0470 · Cited by 72
Self-citation
Real-world evidence supporting Tandem Control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations
Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70
Current Status and Emerging Options for Automated Insulin Delivery Systems
Forlenza, G. P., & Lal, R. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0514 · Cited by 70
Unannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System
Shalit, R., Minsky, N. C., Laron-Hirsh, M., Cohen, O., Kurtz, N., Roy, A., Grosman, B., Benedetti, A., & Tirosh, A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0139 · Cited by 64
Self-citation
Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system
Grassi, B. A., Gómez, A. M., Calliari, L. E., Franco, D. R., Raggio, M., Riera, F., Castro, M., MCVEAN, J. J. F., van den Heuvel, T. R. A., Arrieta, A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15023 · Cited by 58
Self-citation
A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting
Beato-Víbora, P. I., Chico, A. I., Moreno-Fernández, J., Bellido, V., Nattero‐Chávez, L., César, M. J. P., Martínez‐Brocca, M. A., Giménez, M., Aguilera, E., Climent, E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1355 · Cited by 57
Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis
Kovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A. (2022) · Diabetes Care · doi:10.2337/dc22-1217 · Cited by 49
Human-machine co-adaptation to automated insulin delivery: a randomised clinical trial using digital twin technology
Kovatchev, B. P., Colmegna, P. H., Pavan, J., C., J. L. D., Villa-Tamayo, M. F., Koravi, C. L. K., Santini, G., Alix, C., Stumpf, M. M., & Brown, S. A. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01679-y · Cited by 50
Closed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
UK 's Association of British Clinical Diabetologist's Diabetes Technology Network ( ABCD‐DTN ): Best practice guide for hybrid closed‐loop therapy
Griffin, T. P., Gallen, G., Hartnell, S., Crabtree, T. S. J., Holloway, M., Gibb, F. W., Lumb, A. N., Wilmot, E. G., Choudhary, P., & Hussain, S. (2023) · Diabetic Medicine · doi:10.1111/dme.15078 · Cited by 46
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 55
Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes
Tanenbaum, M. L., & COMMISSARIAT, P. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01469-w · Cited by 47
MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control
Lombardo, F., Passanisi, S., Alibrandi, A., Bombaci, B., Bonfanti, R., Delvecchio, M., Candia, F. D., Mozzillo, E., Piccinno, E., Piona, C. A., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0491 · Cited by 41
Real‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis
Yang, Q., Zeng, B., Hao, J., Yang, Q., & Sun, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15718 · Cited by 41
Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control
Lepore, G., Rossini, A., Bellante, R., Corsi, A. M., Scaranna, C., Dodesini, A. R., & Trevisan, R. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01937-5 · Cited by 37
Self-citation
A Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection Technology
Grosman, B., Roy, A., LINTEREUR, L. J., Turksoy, K., Benedetti, A., Cordero, T. L., Vigersky, R. A., MCVEAN, J. J. F., Rhinehart, A. S., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0446 · Cited by 36
Self-citation
The changing landscape of automated insulin delivery in the management of type 1 diabetes
Lakshman, R., Boughton, C. K., & Hovorka, R. (2023) · Endocrine Connections · doi:10.1530/ec-23-0132 · Cited by 43
A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes
Bassi, M., Teliti, M., Lezzi, M., Iosca, A., Strati, M. F., Carmisciano, L., d’Annunzio, G., Minuto, N., & Maggi, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802419 · Cited by 35
Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States
Arunachalum, S., Velado, K., Vigersky, R. A., & Cordero, T. L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088608 · Cited by 35
One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany
Benhamou, P., Adenis, A., Lebbad, H., Tourki, Y., Heredia, M., Gehr, B., Franc, S., & Charpentier, G. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15008 · Cited by 35
Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c
Boucsein, A., Zhou, Y., Michaels, V. R., Haszard, J. J., Jefferies, C., Wiltshire, E. J., Paul, R. G., Parry‐Strong, A., Pasha, M., Petrovski, G., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400185 · Cited by 34
Comparison of two advanced hybrid closed loop in a pediatric population with type 1 diabetes: a real-life observational study
Schiaffini, R., Deodati, A., Nicoletti, M. C., Carducci, C., Ciampalini, P., Lorubbio, A., Matteoli, M. C., Pampanini, V., Patera, I. P., Rapini, N., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01886-z · Cited by 33
Experience with burdens of diabetes device use that affect uptake and optimal use in people with type 1 diabetes
Tanenbaum, M. L., & COMMISSARIAT, P. V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0193 · Cited by 32
Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus
Pintaudi, B., Gironi, I., Nicosia, R., Meneghini, E., Disoteo, O., Mion, E., & Bertuzzi, F. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.03.031 · Cited by 32
One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes
Bassi, M., Patti, L., Silvestrini, I., Strati, M. F., Ponzano, M., Minuto, N., & Maggi, D. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1099024 · Cited by 32
Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study
Šantová, A., Plachý, L., Neuman, V., Pavlı́ková, M., Petruželková, L., Konečná, P., Venháčová, P., Škvor, J., Pomahačová, R., Neumann, D., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1283181 · Cited by 32
The Psychological Implications of Automated Insulin Delivery Systems in Type 1 Diabetes Care
Nefs, G. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.846162 · Cited by 35
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Cordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., MCVEAN, J. J. F., Lee, S. W., Slover, R. H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0123 · Cited by 33
Self-citation
Perioperative Care of Patients Using Wearable Diabetes Devices
Cruz, P., McKee, A. M., Chiang, H.-H., McGill, J. B., Hirsch, I. B., Ringenberg, K. J., & Wildes, T. S. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007115 · Cited by 32
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling
Asgharzadeh, A., Patel, M., Connock, M. J., Damery, S. L., Ghosh, I., Jordan, M., Freeman, K., Brown, A., Court, R. A., Baldwin, S., et al. (2024) · Health Technology Assessment · doi:10.3310/jypl3536 · Cited by 32
Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes
Bhargava, A., Bergenstal, R. M., Warren, M., Thrasher, J. R., Dempsey, M. A., Bode, B. W., LaRocque, J., Carlson, A. L., Keiter, A., Ma, H., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0586 · Cited by 31
Self-citation
Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023
Bassi, M., Franzone, D., Dufour, F., Strati, M. F., Scalas, M., Tantari, G., Aloi, C., Salina, A., d’Annunzio, G., Maghnie, M., et al. (2023) · Life · doi:10.3390/life13030783 · Cited by 34
Glycemic Control in Relation to Technology Use in a Single-Center Cohort of Children with Type 1 Diabetes
Sawyer, A., Sobczak, M., Forlenza, G. P., & Alonso, G. T. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0471 · Cited by 28
Long-term outcomes of an advanced hybrid closed-loop system: A focus on different subpopulations
Beato-Víbora, P. I., Ambrojo-López, A., Fernández-Bueso, M., Gil-Poch, E., & Arroyo-Díez, F. J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110052 · Cited by 27
Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review
Karol, A. B., O’Malley, G., Fallurin, R., & Levy, C. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.001 · Cited by 27
Safety and Glycemic Outcomes During the MiniMed TM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes
Pihoker, C., Shulman, D. I., Forlenza, G. P., Kaiserman, K. B., Sherr, J. L., Thrasher, J. R., Buckingham, B. A., Kipnes, M. S., Bode, B. W., Carlson, A. L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0255 · Cited by 27
Self-citation
Hybrid Closed Loop Using a Do-It-Yourself Artificial Pancreas System in Adults With Type 1 Diabetes
Nanayakkara, N., Sharifi, A., Burren, D., Elghattis, Y., Jayarathna, D. K., & Cohen, N. D. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231153882 · Cited by 28
Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems
Aktürk, H. K., Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T. R. A., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0432 · Cited by 26
Self-citation
Use of diabetes technology in children
Schoelwer, M. J., DeBoer, M. D., & Breton, M. D. (2024) · Diabetologia · doi:10.1007/s00125-024-06218-0 · Cited by 27
Recent advances in closed-loop insulin delivery
Ware, J., & Hovorka, R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154953 · Cited by 28
Exercise and nutrition in type 1 diabetes: Insights from the FinnDiane cohort
Barlovič, D. P., Harjutsalo, V., & Groop, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064185 · Cited by 26
Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes
Seget, S., Rusak, E., Polańska, J., & Jarosz-Chobot, P. A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0148 · Cited by 22
Automated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled Study
McCarthy, O. M., Christensen, M. B., Kristensen, K. B., Schmidt, S., Ranjan, A. G., Bain, S. C., Bracken, R. M., & Nørgaard, K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0009 · Cited by 23
Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single‐centre real‐world study
Eviz, E., Kıllı, N. E., Karakus, K. E., Can, E., Gökçe, T., Mutlu, G. Y., & Hatun, Ş. (2024) · Diabetic Medicine · doi:10.1111/dme.15333 · Cited by 24
Insulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days’ Real-World Data of Children in Two Different Age Groups
Karakus, K. E., Mutlu, G. Y., Gökçe, T., Eviz, E., Can, E., Muradoğlu, S., & Hatun, Ş. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221106194 · Cited by 23
Long‐term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes
Piccini, B., Pessina, B., Casalini, E., Lenzi, L., & Toni, S. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13440 · Cited by 22
Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy
Lepore, G., Borella, N. D., Castagna, G., Ippolito, S., Bonfadini, S., Corsi, A. M., Scaranna, C., Dodesini, A. R., Bellante, R., & Trevisan, R. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0261 · Cited by 22
Self-citation
Improvement of Selected Psychological Parameters and Quality of Life of Patients With Type 1 Diabetes Mellitus Undergoing Transition From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to the MiniMed 780G Advanced Hybrid Closed-Loop System: Post hoc Analysis of a Randomized Control Study
CYRANKA, K. M., Matejko, B., Juza, A., Kieć‐Wilk, B., Krzyżowska, S., Cohen, O., Silva, J. D., Lushchyk, M. L., Malecki, M. T., & Klupa, T. (2022) · JMIR Formative Research · doi:10.2196/43535 · Cited by 24
Self-citation
A Real-World Prospective Study of the Effectiveness and Safety of Automated Insulin Delivery Compared With Other Modalities of Type 1 Diabetes Treatment During Ramadan Intermittent Fasting
Al‐Sofiani, M. E., Alharthi, S. K., Albunyan, S., Alzaman, N. S., Klonoff, D. C., & Alguwaihes, A. M. (2024) · Diabetes Care · doi:10.2337/dc23-1968 · Cited by 22
Development and Future of Automated Insulin Delivery (AID) Systems
Garg, S. K., & MCVEAN, J. J. F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0467 · Cited by 25
MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users
Elbarbary, N. S., & Ismail, E. A. R. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01184-w · Cited by 20
MiniMed TM 780G Advanced Hybrid Closed-Loop System Study in Pregnant Women with Type 1 Diabetes
Guibert, C., Amoura, L., Rakotoarisoa, L., Plat, F., Sonnet, E., Lablanche, S., Tréglia, C., Sarde, E., Leca, V., Rimareix, F., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0267 · Cited by 21
Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems
Bahillo-Curieses, P., Fernández-Velasco, P., Pérez-López, P., Martínez, A. M. V., de la Marca, M. D. L. O. N., & Díaz-Soto, G. (2024) · Endocrine · doi:10.1007/s12020-024-03881-6 · Cited by 24
A systematic literature review and meta‐analysis of real‐world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes
Pöhlmann, J., Smith‐Palmer, J., Serné, E. H., Tuomaala, A., JENDLE, J. H., Choudhary, P., Bosi, E., Mohan, V., van den Heuvel, T. R. A., Cohen, O., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70161 · Cited by 21
Self-citation
Closed-Loop and Artificial Intelligence–Based Decision Support Systems
Nimri, R., Phillip, M., & Kovatchev, B. P. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2505 · Cited by 21
The Advanced Hybrid Closed Loop Improves Glycemia Risk Index, Continuous Glucose Monitoring Index, and Time in Range in Children with Type 1 Diabetes: Real-World Data from a Single Center Study
Eviz, E., Mutlu, G. Y., Karakus, K. E., Can, E., Gökçe, T., Muradoğlu, S., & Hatun, Ş. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0112 · Cited by 19
Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
Forlenza, G. P., Dai, Z., Niu, F., & Shin, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0459 · Cited by 20
Self-citation
One-Year Follow-Up of Advanced Hybrid Closed-Loop System in Adults with Type 1 Diabetes Previously Naive to Diabetes Technology: The Effect of Switching to a Calibration-Free Sensor
Matejko, B., Juza, A., Kieć‐Wilk, B., CYRANKA, K. M., Krzyżowska, S., Cohen, O., Malecki, M. T., & Klupa, T. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0059 · Cited by 18
Self-citation
The significance of coefficient of variation as a measure of hypoglycaemia risk and glycaemic control in real world users of the automated insulin delivery MiniMed 780G system
Castañeda, J., Arrieta, A., van den Heuvel, T. R. A., & Cohen, O. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15139 · Cited by 18
Self-citation
Carbohydrate Intake and Closed-Loop Insulin Delivery System during Two Subsequent Pregnancies in Type 1 Diabetes
Munda, A., Kovacic, C., & Barlovič, D. P. (2022) · Metabolites · doi:10.3390/metabo12111137 · Cited by 17
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial
McCarthy, O. M., Christensen, M. B., Kristensen, K. B., Schmidt, S., Ranjan, A. G., Bain, S. C., Bracken, R. M., & Nørgaard, K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0542 · Cited by 17
Twelve‐month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed‐loop therapy outcomes versus conventional therapy in adults with type 1 diabetes
Shannon, N., Castañeda, J., Choudhary, P., Kolassa, R., Keuthage, W., Kroeger, J., Thivolet, C. H., Evans, M. L., Ré, R., Cellot, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15217 · Cited by 18
Self-citation
MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience
Rachmiel, M., Lebenthal, Y., Mazor‐Aronovitch, K., Brener, A., Levek, N., Jacobi‐Polishook, T., Ari, T. B., Abiri, S., Landau, Z., & Pinhas‐Hamiel, O. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0081 · Cited by 17
Automated Insulin Delivery: A Milestone on the Road to Insulin Independence in Type 1 Diabetes
Limbert, C., Kowalski, A. J., & Danne, T. (2024) · Diabetes Care · doi:10.2337/dci24-0007 · Cited by 17
Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: impact on glycemic control and neuropsychological tests in the real world
Amigó, J., Ortiz-Zúñiga, Á., de Urbina, A. M. O., Sánchez, M., Dos-Santos, M., Abad, M., Cuadra, F., Simó, R., Hernández, C., & Simó-Servat, O. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110730 · Cited by 15
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting
Gardner, D. S.-L., Lakkad, M., Qiu, Z., Inoue, Y., CHANDRAN, S. R., & Wherry, K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0455 · Cited by 16
Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review
Mameli, C., Smylie, G. M., Galati, A., Rapone, B., Cardona‐Hernandez, R., Zuccotti, G., & Delvecchio, M. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04833-4 · Cited by 15
Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System
Kesavadev, J., Basanth, A., Krishnan, G., Shankar, A., Sanal, G., & Jothydev, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01427-z · Cited by 16
Real-World Diabetes Technology: Overcoming Barriers and Disparities
Messer, L. H., Addala, A., & WEINZIMER, S. A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2511 · Cited by 14
Commercial hybrid closed-loop systems available for a patient with type 1 diabetes in 2022
Seget, S., Tekielak, A., Rusak, E., & Jarosz-Chobot, P. A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.126359 · Cited by 14
Prolonged Use of an Automated Insulin Delivery System Improves Sleep in Long-Standing Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia
Malone, S. K., MATUS, A. M., Flatt, A. J., Peleckis, A. J., Grunin, L., Yu, G., Jang, S., Weimer, J. E., Lee, I., Rickels, M. R., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231182406 · Cited by 14
An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm
Roy, A., Grosman, B., Benedetti, A., Engheta, B., Miller, D. M., Laron-Hirsh, M., Cohen, Y. C., Ré, R., Edd, S. N., Vigersky, R. A., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0529 · Cited by 14
Self-citation
Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational study
Cherubini, V., Faragalli, A., Arnaldi, C., Bassi, M., Bonfanti, R., Bracciolini, G., Cardella, F., Bo, S. D., Delvecchio, M., Candia, F. D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111621 · Cited by 15
Comparative Effectiveness of Hybrid Closed-Loop Automated Insulin Delivery Systems Among Patients with Type 1 Diabetes
Folk, S. Y. L., Zappe, J., Wyne, K. L., & Dungan, K. M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241234948 · Cited by 14
Real-world data on the Minimed 780G advanced hybrid closed-loop system use during type 1 diabetes pregnancy: One centre observational study
Munda, A., Kovacic, C., & Barlovič, D. P. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108795 · Cited by 15
Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring
Herguido, N. G., Amuedo, S., Bellido, V., Gallardo, G. L., Losada, F., Pérez-Morales, A., Trillo, C. A. R., & Moreno, A. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0287 · Cited by 13
(Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise
Zimmer, R. T., Auth, A., Schierbauer, J., Haupt, S., Wachsmuth, N. B., Zimmermann, P., Voit, T., Battelino, T., Sourij, H., & Moser, O. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0293 · Cited by 15
Self-citation
Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes
Singh, R., Imberg, H., Ahmadi, S. S., Hallström, S., JENDLE, J. H., Tengmark, B.-O., Folino, A., Marie, E., & Lind, M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241242386 · Cited by 13
Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care
Dekker, P., van den Heuvel, T. R. A., Arrieta, A., Castañeda, J., Mul, D., Veeze, H. J., Cohen, O., & Aanstoot, H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241290259 · Cited by 16
Self-citation
Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience
Halim, B., Abraham, M. B., Manos, G., Arrieta, A., Dai, Z., Vogrin, S., Lu, J., MacIsaac, R. J., Ekinci, E. I., Davis, E. A., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0348 · Cited by 12
Self-citation
MiniMed 780G System Use in Type 1 Diabetes During Ramadan Intermittent Fasting: A Systematic Literature Review and Expert Recommendations
Elbarbary, N. S., Alguwaihes, A. M., ZARIF, H. A., Hassanein, M., Deeb, A., Petrovski, G., Aldahash, R., Amoudi, R. A., Hussain, S., Ibrahim, M. A., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0200 · Cited by 13
Generating real‐world evidence on diabetes technology using the CareLink Personal data management system
van den Heuvel, T. R. A., Castañeda, J., Arrieta, A., Voelker, B., Cohen, O., Liu, M., Garelli, F. D., & Shin, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15868 · Cited by 13
Self-citation
A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People With Type 1 Diabetes
Gera, S., Iyer, J., Meighan, S. S., March, C. A., & Marks, B. E. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.004 · Cited by 13
Blood glucose monitoring devices: current considerations
Sly, B., & Taylor, J. (2023) · Australian Prescriber · doi:10.18773/austprescr.2023.013 · Cited by 11
Insulin Pump Therapy Efficacy and Key Factors Influencing Adherence in Pediatric Population—A Narrative Review
Trandafir, L. M., Moisă, Ș. M., Vlaiculescu, M. V., Butnariu, L. I., Boca, L. O., Constantin, M. M., Lupu, P. M., Brinza, C., Temneanu, O. R., & Burlacu, A. (2022) · Medicina · doi:10.3390/medicina58111671 · Cited by 10
A comparison of the usage of an open-source automated insulin delivery system and the MiniMed™ 780 G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group
Landau, Z., Lebenthal, Y., Mazor‐Aronovitch, K., Brener, A., Levek, N., Jacobi‐Polishook, T., Ari, T. B., Abiri, S., Haim, A., Nir, J., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03683-w · Cited by 10
Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial
Boucsein, A., Zhou, Y., Haszard, J. J., Jefferies, C., Wiltshire, E. J., Styles, S. E., Crocket, H. R., Galland, B. C., Pasha, M., Petrovski, G., et al. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01397-4 · Cited by 10
The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes
Jalilova, A., Pilan, B. Ş., Demir, G., Özbaran, B., Balkı, H. G., Arslan, E., Köse, S., Özen, S., Darcan, Ş., & Gökşen, D. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05551-1 · Cited by 10
Simplified Meal Management in Adults Using an Advanced Hybrid Closed-Loop System
Minsky, N. C., Shalit, R., Benedetti, A., Laron-Hirsh, M., Cohen, O., Kurtz, N., Roy, A., Grosman, B., & Tirosh, A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0224 · Cited by 10
Self-citation
Long‐term use of Minimed™ 780G in children and adolescents with type 1 diabetes under real‐world conditions: The benefits of optimal settings
Bombaci, B., Passanisi, S., Calderone, M., Macrì, F., Lombardo, F., & Salzano, G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16226 · Cited by 12
Impact on glucometric variables and quality of life of the advanced hybrid closed‐loop system in pediatric and adolescent type 1 diabetes
Jurado, A. L., Gómez‐Perea, A., Jiménez, A. B. A., Tapia‐Ceballos, L., Becerra‐Paz, I., Lirio, M. F. M., Jabato, F. M., & Gea, I. L. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13426 · Cited by 10
Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System
Newman, C., Hartnell, S., Wilinska, M. E., Alwan, H., & Hovorka, R. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231187915 · Cited by 10

Authors: Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O.
Affiliations: Medtronic (Switzerland) (CH)
Ospedale Papa Giovanni XXIII (IT)
University of Ljubljana (SI)
Medtronic (Netherlands) (NL)
Medtronic, Northridge, California, USA.
Medtronic (United States) (US)
Corresponding author: Cohen, Ohad
ORCID: Lepore, Giuseppe
Battelino, Tadej
Arrieta, Arcelia
Castañeda, Javier
Shin, John
Cohen, Ohad
Venue: Diabetes Technology & Therapeutics
Publisher: SAGE Publications
Published: 2022-01-31
Volume: 24
Issue: 2
Pages: 113-119
ISSN: 1520-9156 (ISSN-L)
1557-8593
DOI: 10.1089/dia.2021.0203
PMC: PMC8817690
OpenAlex: W3201039184
Cited by: 229
References: 26
Citations by year: 2026: 29 · 2025: 35 · 2024: 61 · 2023: 67 · 2022: 36
FWCI: 30.80
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Diabetes Technology & Therapeutics (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: MiniMed 780G, hybrid closed-loop insulin delivery, type 1 diabetes, real-world performance, glucose management indicator, time in range, glycemic control, continuous glucose monitoring
MeSH terms: Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Retrospective Studies, Blood Glucose Self-Monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks